Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors

NCT06907043 is registered in ClinicalTrials.gov with Eikon Therapeutics as lead sponsor.

NCT NCT06907043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06907043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors
Lead sponsor
Eikon Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 30, 2025
Completion date
December 31, 2028
Enrollment
130 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors